6.11
+0.83(+15.72%)
Currency In USD
| Previous Close | 5.28 |
| Open | 5.26 |
| Day High | 6.49 |
| Day Low | 5.22 |
| 52-Week High | 15.36 |
| 52-Week Low | 4.3 |
| Volume | 877,978 |
| Average Volume | 272,546 |
| Market Cap | 160.76M |
| PE | -3 |
| EPS | -2.04 |
| Moving Average 50 Days | 7.32 |
| Moving Average 200 Days | 7.69 |
| Change | 0.83 |
If you invested $1000 in CVRx, Inc. (CVRX) since IPO date, it would be worth $218.21 as of February 21, 2026 at a share price of $6.11. Whereas If you bought $1000 worth of CVRx, Inc. (CVRX) shares 3 years ago, it would be worth $862.99 as of February 21, 2026 at a share price of $6.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
GlobeNewswire Inc.
Feb 12, 2026 9:05 PM GMT
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascu
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
GlobeNewswire Inc.
Jan 29, 2026 9:10 PM GMT
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascu
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
GlobeNewswire Inc.
Jan 22, 2026 9:05 PM GMT
Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is Supported by CMS Category B IDE CoverageMINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device